MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Monday reported a fourth-quarter loss of $10.8 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the Mountain View, California-based company said it had a loss of 21 cents.
The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share.
The biopharmaceutical company posted revenue of $9.3 million in the period, missing Street forecasts. Five analysts surveyed by Zacks expected $9.5 million.
For the year, the company reported a loss of $38 million, or 76 cents per share, swinging to a loss in the period. Revenue was reported as $42.9 million.
ChemoCentryx shares have decreased slightly more than 5 percent since the beginning of the year. In the final minutes of trading on Monday, shares hit $10.33, a decline of 15 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI